<DOC>
	<DOCNO>NCT01679041</DOCNO>
	<brief_summary>The purpose study evaluate toxicity effectiveness high dose chemotherapy HPC transplant Multiple Sclerosis fail least two line therapy</brief_summary>
	<brief_title>High Dose Chemo With Stem Cell Transplant Treatment Multiple Sclerosis That Failed Prior Treatment</brief_title>
	<detailed_description>Multiple sclerosis inflammatory autoimmune disease characterize loss myelin axonal damage , typical contrast-enhanced MRI focus image counterpart . MS show three main pattern clinical course : relapsing/remitting , primary progressive secondary progressive.Concerning disease pattern , secondary progressive standard indication , avoid overtreatment relapsing/remitting patient ineffectual treatment primary relapsing patient . Currently , MS common autoimmune disease treat autologous HPC transplant ( Fagius et al , 2009 ; Burt et al , 2009 ; Saccardi et al , 2006 ) . More 350 consecutive case report EBMT last decade . Most patient underwent autologous HPC transplant MS early study secondary progressive MS , relatively few relapse remit disease , Kurtzke Expanded Disability Status Scale ( EDSS ) 3.0-9.5 time transplant . Significant objective subjective improvement report 70 % patient . The follow conditioning regimen use , Alemtuzumab , Fludarabine , Cyclophosphamide use patient . Prophylaxis Acyclovir , Levaquin , Fluconazole give prevent infection . The autologous HPC infuse within 48-72 hour complete chemotherapy . The patient receive additional supportive care medication treatment necessary . Neutrophil engraftment define day ANC rise &gt; 500 cells/ml two consecutive day . Platelet engraftment define first day platelet count rise &gt; 20,000/ml 7-day interval without transfusion support .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Age 1860 , inclusive Patients carry diagnosis multiple sclerosis , accord McDonald 's criterion diagnosis ( Polman et al , 2011 ) . Must neurologist provide primary care MS willing evaluate multiple sclerosis two neurologist coinvestigators protocol . Must document HIV negative . An EDSS 3.5 5.5 Patients must able give write consent . Inflammatory disease despite primary disease modify therapy least 6 month interferon another disease modify therapy , include fingolimod , glativamir , natalizumab , mitoxantrone . Failure define two clinical relapse document neurologic change ( exclude sensory change ) within year prior study . ( NOTE : Relapses must require treatment corticosteroid ) . Failure may also define one relapse ( exclude sensory change ) treat methylprednisone , separate occasion within previous 12 month , evidence active inflammation ( i.e . gadolinium enhancement MRI scan CNS ) . No previous history allergic reaction cyclophosphamide , GCSF mesna Patients must pregnant Failure accept comprehend irreversible sterility potential side effect therapy . Life expectancy 6 month No evidence myelodysplastic syndrome peripheral blood smear Not allergic cyclophosphamide , mesna , fludarabine alemtuzumab Baseline serum creatinine must &lt; 1.5 mg/dL , leave ventricular ejection fraction &gt; 55 % , adequate pulmonary function ( oxygen saturation room air &gt; 90 % ) , AST ALT &gt; 2x upper limit normal , history previous active malignancy , except localize cutaneous basal squamous cell carcinoma situ cervix . Diagnosis primary progressive MS .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>